Evidence map›Paper›PMID 36561245›Full record

ArticleIranian journal of public health2022

The Economic Burden of Acute Myeloid Leukemia in Iran.

Vahid Alipour, Soroush Rad, Shahin Nargesi, Fateme Mezginejad, Reza Jahangiri, Zeinab Dolatshahi, Seyed Asadollah Mousavi, Zahra Moshkani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vahid AlipourHealth Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
Soroush RadHematology, Oncology, and Hematopoietic Stem Cell Transportation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Shahin NargesiDepartment of Health Management and Economics, Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran.
Fateme MezginejadCellular and Molecular Research Center, Birjand Iran University of Medical Science, Birjan, Iran.
Reza JahangiriDepartment of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Zeinab DolatshahiDepartment of Health Policy, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Seyed Asadollah MousaviHematology, Oncology, and Hematopoietic Stem Cell Transportation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Zahra MoshkaniHealth Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aimed to estimate the economic burden of AML in Iran for 2020. Methods: In this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited. Results: Approximately 98% of patients with AML received induction therapy. The AML economic burden was $33,243,107.39. Indirect costs accounted for 60% (21,593,764.4$) of this amount, and direct medical costs and direct non-medical costs make up for 19% (6,359,380.88$) and 16% (5,289,962.11$) of this estimated economic burden, respectively. Conclusion: The economic burden of AML in Iran is very remarkable and due to the increasing prevalence of this disease, it is expected to increase gradually. Having insights into the costs associated with the disease provide an excellent opportunity for health policymakers and managers to effectively improve resource allocation.

Indexed as

Acute myeloid leukemiaConsolidation therapyEconomic burdenIran

Identifiers

PMID36561245
PMCPMC9745398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.